Updates in Immunotherapy & Targeted Therapy in Gastrointestinal Cancers

May Cho, MD.



Conflicts of Interest

Consultant:

Incyte, Eisai, Amgen, Ipsen, Astellas, Taiho, Exelixis, AstraZeneca

Updates in 2019




Figure 1. Colon Anatomy. Adapted from The Surgeons Collective. 2019, Retrieved from https://www.thesurgeonscollective.com.au/treatments/cancer-surgery-perth

Updates in 2019





Figure 1. Colon Anatomy. Adapted from The Surgeons Collective. 2019, Retrieved from https://www.thesurgeonscollective.com.au/treatments/cancer-surgery-perth

Case

- A 58 yo man with hepatitis C cirrhosis presents with abdominal pain, vomitting, and 25# weight loss
- Imaging reveals multiple liver lesions that enhance in arterial phase and washout in the portal-venous phase
 - Multiple lung metastases seen
- Based on his labs and exam, his Child-Pugh score is A6





Case – Question

- What is your next step?
- 1. Liver biopsy
- 2. Transplant
- 3. Sorafenib
- 4. Lenvatinib
- 5. Atezolizumab/Bevacizumab

Atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: Phase 3 results from IMbrave150

Ann-Lii Cheng,¹ Shukui Qin,² Masafumi Ikeda,³ Peter R. Galle,⁴ Michel Ducreux,⁵ Andrew X. Zhu,⁶ Tae-You Kim,⁷ Masatoshi Kudo,⁸ Valeriy Breder,⁹ Philippe Merle,¹⁰ Ahmed Kaseb,¹¹ Daneng Li,¹² Wendy Verret,¹³ Derek-Zhen Xu,¹⁴ Sairy Hernandez,¹³ Juan Liu,¹⁴ Chen Huang,¹⁴ Sohail Mulla,¹⁵ Ho Yeong Lim,¹⁶ Richard S. Finn¹⁷

¹National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan; ²People's Liberation Army Cancer Center, Jinling Hospital, Nanjing, People's Republic of China; ³National Cancer Center Hospital East, Kashiwa, Japan; ⁴University Medical Center Mainz, Mainz, Germany; ⁵Gustave Roussy Cancer Center, Villejuif, France; ⁶Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA; ⁷Seoul National University College of Medicine, Seoul, Korea; ⁸Kindai University Faculty of Medicine, Osaka, Japan; ⁹N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; ¹⁰Hospital La Croix-Rousse, Lyon, France; ¹¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹²City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA; ¹³Genentech, Inc., South San Francisco, CA, USA; ¹⁴Roche Product Development, Shanghai, People's Republic of China; ¹⁵Hoffmann-La Roche Limited, Mississauga, ON, Canada; ¹⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; ¹⁷Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Background

- Multikinase inhibitors sorafenib and lenvatinib are the preferred first-line systemic treatments for unresectable hepatocellular carcinoma (HCC)¹⁻⁷
 - While these agents have had modest effects on overall survival, they are both associated with considerable side effects
 - With sorafenib, the median overall survival ranges from ≈ 12 to 14 months; however, no treatment has demonstrated a statistically significant and clinical meaningful improvement in overall survival beyond sorafenib in over a decade
- A Phase 1b study (NCT02715531) of atezolizumab (anti–PD-L1) + bevacizumab (anti-VEGF) in patients with advanced HCC demonstrated a tolerable safety profile and promising antitumour activity, with an objective response rate of 36% and a median progression-free survival of 7.3 months⁸⁻⁹
- Here we report the results of IMbrave150, a global, open-label, Phase 3, randomised study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable HCC who have not received prior systemic therapy

1. NCCN Clinical Practice Guidelines. V2.2019; 2. Vogel A, et al. Ann Onc 2019; 3. Cheng AL, et al. Lancet Oncol 2009; 4. Kudo M, et al. Lancet 2018; 5. Llovet JM, et al. N Engl J Med 2008; 6. Boige V, et al. Oncologist 2012; 7. Finn RS, et al. Expert Rev Anticancer 2009; 8. Lee MS, et al. ESMO 2019; 9. Hsu C-H, et al. ESMO Asia 2019.


IMbrave150 study design

Key eligibility

- Locally advanced or metastatic and/or unresectable HCC
- No prior systemic therapy

Stratification

- Region (Asia, excluding Japan^a/rest of world)
- ECOG PS (0/1)
- Macrovascular invasion (MVI) and/or extrahepatic spread (EHS) (presence/absence)
- Baseline α-fetoprotein (AFP; < 400/≥ 400 ng/mL)



- OS
- IRF-assessed PFS per RECIST 1.1

Key secondary endpoints (in testing strategy)

Until loss of

clinical

benefit or

un-

acceptable

toxicity

IRF-assessed ORR per RECIST 1.1

Atezolizumab 1200 mg IV q3w

bevacizumab

15 mg/kg q3w

 $N = 501^{b}$

Sorafenib

400 mg BID

(open-label)

R

2:1

IRF-assessed ORR per HCC mRECIST

^a Japan is included in rest of world.

^b An additional 57 Chinese patients in the China extension cohort were not included in the global population/analysis.

ESMO Asia 2019


Survival

follow-up

IMbrave150 baseline characteristics (ITT)

Characteristic	Atezo + Bev (n = 336)	Sorafenib (n = 165)
Median age (range), years	64 (26-88)	66 (33-87)
Sex, male, n (%)	277 (82)	137 (83)
Region, n (%)		
Asia (excluding Japan ^a)	133 (40)	68 (41)
Rest of world	203 (60)	97 (59)
ECOG PS 1, n (%)	127 (38)	62 (38)
Child-Pugh class, n (%)		
A B	333 (99) 1 (< 1)	165 (100) 0
BCLC staging at study entry, n (%)		
A B C	8 (2) 52 (15) 276 (82)	6 (4) 26 (16) 133 (81)
Aetiology of HCC, n (%)		
HBV HCV Non-viral	164 (49) 72 (21) 100 (30)	76 (46) 36 (22) 53 (32)
AFP ≥ 400 ng/mL, n (%)	126 (38)	61 (37)
EHS, n (%)	212 (63)	93 (56)
MVI, n (%)	129 (38)	71 (43)
EHS and/or MVI, n (%)	258 (77)	120 (73)
Prior TACE, n (%)	130 (39)	70 (42)
Prior radiotherapy, n (%)	34 (10)	17 (10)


^a Japan is included in rest of world.



OS: co-primary endpoint

NE, not estimable. a 96 patients (29%) in the Atezo + Bev arm vs 65 (39%) in the sorafenib arm had an event. B HR and P value were from Cox model and logrank test and were stratified by geographic region (Asia vs rest of world, including Japan), AFP level (< 400 vs ≥ 400 ng/mL) at baseline and MVI and/or EHS (ves vs no) per IxRS. "The 2-sided P value boundary based on 161 events is 0.0033. Data cutoff 20 Aug 2010 median survival follow-up 8.6 mo

Confirmed PFS^a: co-primary endpoint



^a Assessed by IRF per RECIST 1.1. ^b 197 patients (59%) in the Atezo + Bev arm vs 109 (66%) in the sorafenib arm had an event. ^c HR and *P* value were from Cox model and log-rank test and were stratified by geographic region (Asia vs rest of world, including Japan), AFP level (< 400 vs \geq 400 ng/mL) at baseline and MVI and/or EHS (yes vs no) per IxRS. ^d The 2-sided *P* value boundary is 0.002. Data cutoff, 29 Aug 2019; median survival follow-up, 8.6 mo.

OS subgroups

Characteristic (n)	Atezo + Bev mOS, mo (n = 336)	Sorafenib mOS, mo (n = 165)		HR (95% CI)ª
All patients (501)	NE	13.2	[0.58 (0.42, 0.79)
Asia (excluding Japan ^b) (201)	NE	13.1		0.53 (0.32, 0.87)
Rest of world (300)	NE	13.2	□	0.65 (0.44, 0.98)
ECOG PS 0 (312)	NE	13.9	· · · · · · · · · · · · · · · · · · ·	0.67 (0.43, 1.06)
ECOG PS 1 (189)	NE	7.4		0.51 (0.33, 0.80)
BCLC stage B ^c (78)	NE	14.9	↓ → →	1.09 (0.33, 3.53)
BCLC stage C ^c (409)	NE	11.4		0.54 (0.39, 0.75)
HBV HCC (240)	NE	13.9	[€]	0.51 (0.32, 0.81)
HCV HCC (108)	NE	13.1	i −−−−−1	0.43 (0.22, 0.87)
Non-viral HCC (153)	NE	14.9	Ⅰ	0.91 (0.52, 1.60)
AFP ≥ 400 ng/mL (187)	12.8	9.1	· · · · · · · · · · · · · · · · · · ·	0.68 (0.43, 1.08)
AFP < 400 ng/mL (314)	NE	13.9		0.52 (0.34, 0.81)
EHS and/or MVI (378)	NE	10.4		0.55 (0.39, 0.77)
No EHS and MVI (123)	NE	14.9	F	0.69 (0.29, 1.65)
NE, not estimable. ^a Unstratified HR shown for all characteristics where stratified HR is shown. ^b Japan is inclu-	ded in rest of world.		0.2 1.0 2 Atezo + Bev better Sorafenib better	er 🔸

° BCLC stage A not shown, as there were only 14 patients; thus, estimation is not meaningful.

Data cutoff, 29 Aug 2019; median survival follow-up, 8.6 mo.

Response rate and duration of response

	IRF REC	CIST 1.1	IRF HCC r	CC mRECIST	
	Atezo + Bev (n = 326)	Sorafenib (n = 159)	Atezo + Bev (n = 325) ^a	Sorafenib (n = 158)	
Confirmed ORR , n (%) (95% Cl)	89 (27) (23, 33)	19 (12) (7, 18)	108 (33) (28, 39)	21 (13) (8, 20)	
CR	18 (6)	0	33 (10)	3 (2)	
PR	71 (22)	19 (12)	75 (23)	18 (11)	
Stratified <i>P</i> value ^b	< 0.0	0001	< 0.0	001	
SD, n (%)	151 (46)	69 (43)	127 (39)	66 (42)	
PD, n (%)	64 (20)	39 (25)	66 (20)	40 (25)	
DCR, n (%)	240 (74)	88 (55)	235 (72)	87 (55)	
Ongoing response, n (%) ^c	77 (87)	13 (68)	84 (78)	13 (62)	
Median DOR, months (95% CI)	NE	6.3 (4.7, NE)	NE	6.3 (4.9, NE)	
Event-free rate at 6 months, n (%)	88	59	82	63	


^a IRF HCC mRECIST–evaluable population was based on patients who presented with measurable disease at baseline per HCC mRECIST criteria. ^b Stratification factors included geographic region (Asia vs rest of world, including Japan), AFP level (< 400 vs \geq 400 ng/mL) at baseline and MVI and/or EHS (yes vs no) per IxRS. ^c Denominator is patients with confirmed CR/PR. Data cutoff 29 Aug 2019; median survival follow-up, 8.6 mo.

PFS subgroups

Characteristic (n)	Atezo + Bev mPFS, mo (n = 336)	Sorafenib mPFS, mo (n = 165)		HR (95% CI)ª
All patients (501)	6.8	4.3	Ⅰ	0.59 (0.47, 0.76)
Asia (excluding Japan ^b) (201)	7.7	2.8		0.46 (0.31, 0.67)
Rest of world (300)	6.7	4.9	[●]	0.70 (0.52, 0.96)
ECOG PS 0 (312)	7.9	4.8		0.57 (0.42, 0.78)
ECOG PS 1 (189)	5.6	4.0	I → 1	0.63 (0.44, 0.91)
BCLC stage B ^c (78)	NE	8.6	↓	0.65 (0.33, 1.30)
BCLC stage C ^c (409)	6.4	4.1		0.58 (0.45, 0.75)
HBV HCC (240)	6.7	2.8		0.47 (0.33, 0.67)
HCV HCC (108)	8.3	5.8		0.69 (0.39, 1.20)
Non-viral HCC (153)	7.1	5.6		0.71 (0.47, 1.08)
AFP ≥ 400 ng/mL (187)	5.2	4.1	→	0.79 (0.54, 1.16)
AFP < 400 ng/mL (314)	8.3	4.4		0.49 (0.36, 0.66)
EHS and/or MVI (378)	6.1	4.0		0.53 (0.41, 0.70)
No EHS and MVI (123)	9.9	8.6	□	0.72 (0.42, 1.24)
NE, not estimable. ^a Unstratified HR shown for all characteristics where stratified HR is shown. ^b Japan is inclue ^c BCLC stage A not shown, as there were only	ded in rest of world.	na 2000 no 5000 no	0.2 1.0 2 Atezo + Bev better Sorafenib better	→

Data cutoff, 29 Aug 2019; median survival follow-up, 8.6 mo.

Safety^a ≥ 10% frequency of AEs in either arm and > 5% difference between arms




PPE, palmar-plantar erythrodysaesthesia.

^a Safety-evaluable population.

Patient-reported outcomes^a

 Atezolizumab + bevacizumab delayed the time to deterioration of patient-reported quality of life compared with sorafenib



EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire for Cancer; TTD, time to deterioration.

^a Pre-specified secondary endpoint that was not formally tested; EORTC QLQ-C30 administered every 3 weeks on treatment and every 3 months after treatment

discontinuation or progression. ^b Time to deterioration defined as first decrease from baseline of \geq 10 points¹ in the patient-reported health-related global health status/guality of

life (GHS/QoL) scale of the EORTC QLQ-C30 maintained for 2 consecutive assessments or 1 assessment followed by death from any cause within 3 weeks.

1. Osoba D, et al. J Clin Oncol. 1998.

Data cutoff, 29 Aug 2019; median survival follow-up, 8.6 mo.

IMbrave150 conclusions

• IMbrave150 demonstrated statistically significant and clinically meaningful improvement with atezolizumab + bevacizumab over sorafenib for OS and IRF-assessed PFS per RECIST 1.1

Co-primary endpoints

- OS HR, 0.58 (95% CI: 0.42, 0.79); *P* = 0.0006
- IRF-PFS HR, 0.59 (95% CI: 0.47, 0.76); *P* < 0.0001 _____ in ITT population
- PFS and OS benefits were generally consistent across subgroups
- Statistically significant and clinically meaningful improvements were seen in ORR and responses were durable with atezolizumab + bevacizumab
- The safety and tolerability profile of atezolizumab + bevacizumab was in line with the known safety profiles of each individual component and the underlying disease
- Treatment with atezolizumab + bevacizumab resulted in a clinically meaningful delay in deterioration of patient-reported quality of life vs sorafenib
- Atezolizumab + bevacizumab should be considered a practice-changing treatment for patients with unresectable HCC who have not received prior systemic therapy

Case – Question

- What is your next step?
- 1. Liver biopsy
- 2. Transplant
- 3. Sorafenib
- 4. Lenvatinib
- 5. Atezolizumab/Bevacizumab




Figure 1. Colon Anatomy. Adapted from The Surgeons Collective. 2019, Retrieved from https://www.thesurgeonscollective.com.au/treatments/cancer-surgery-perth

Case

- A 77 yo man with diabetes, CKD presents with cough and CT shows 12.3 X 8.2 X 13.7 cm liver lesion, Porta hepatis adenopathy, portocaval adenopathy.
- Underwent palliative cisplatin and gemcitabine, cisplatin held due to AKI on CKD. Then found to have progression.
- Next Generation Sequencing shows IDH1 mutation.



Case – Question #1

- What is your next step?
- 1. FOLFOX
- 2. FOLFIRI
- 3. Abraxane
- 4. Ivosidenib

ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation


Ghassan K. Abou-Alfa,^{1,2} Teresa Maraculla,³ Milind Javle,⁴ R. Kate Kelley,⁵ Sam Lubner,⁶ Jorge Adeva,⁷ James M. Cleary,⁸ Daniel V. Catenacci,⁹ Mitesh J. Borad,¹⁰ John Bridgewater,¹¹ William P. Harris,¹² Adrian G. Murphy,¹³ Do-Youn Oh,¹⁴ Jonathan Whisenant,¹⁵ Bin Wu,¹⁶ Liewen Jiang,¹⁶ Camelia Gliser,¹⁶ Shuchi S. Pandya,¹⁶ Juan W. Valle,¹⁷ Andrew X. Zhu¹⁸

 ¹Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ²Weill Medical College at Cornell University, New York, NY, USA; ³Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ⁴MD Anderson Cancer Center, Houston, TX, USA; ⁵University of California San Francisco, San Francisco, CA, USA; ⁶University of Wisconsin Carbone Cancer Center, Madison, WI, USA; ⁷Hospital Universitario 12 de Octubre, Madrid, Spain; ⁸Dana-Faber Cancer Institute, Boston, MA, USA; ⁹University of Chicago Medical Center, Chicago, IL, USA; ¹⁰Mayo Clinic Cancer Center, Phoenix, AZ, USA;
¹¹UCL Cancer Institute, London, UK; ¹²University of Washington, Seattle, WA, USA; ¹³Johns Hopkins University, Baltimore, MD, USA; ¹⁴Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ¹⁵Utah Cancer Specialists, Salt Lake City, UT, USA; ¹⁶Agios Pharmaceuticals, Inc., Cambridge, MA, USA; ¹⁷University of Manchester, The Christie NHS Foundation Trust, Manchester, UK; ¹⁸Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

Presented at the European Society for Medical Oncology Congress, September 27- October 1, 2019, Barcelona, Spain

IDH1 mutations in advanced cholangiocarcinoma


- Advanced cholangiocarcinoma is an aggressive rare cancer with treatment options limited primarily to chemotherapy¹
- IDH1 mutations occur in up to 20% of cholangiocarcinoma and do not confer a favorable prognosis¹
- Ivosidenib (AG-120) is a first-in-class, oral, targeted, small-molecule inhibitor of the mutant IDH1 (mIDH1) protein,² and is FDA-approved for mIDH1 R/R AML and ND AML not eligible for intensive chemotherapy³
- A phase 1 study of ivosidenib included 73 previously treated mIDH1 cholangiocarcinoma patients and was associated with: median PFS, 3.8 months; 6- and 12-month PFS rates, 40.1% and 21.8%, respectively; and median OS 13.8 months⁴



2-HG=D-2-hydroxyglutarate; α-KG=alpha-ketoglutarate; AML=acute myeloid leukemia; FDA=Food and Drug Administration; Me=methyl groups; ND=newly-diagnosed; OS=overall survival; PFS=progression-free survival; R/R=relapsed/refractory.

1. Boscoe AN, et al. J Gastrointest Oncol. 2019;10:751-765. 2. Popovici-Muller J, et al. ACS Med Chem Lett. 2018;9:300-305. 3. TIBSOVO highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Accessed August 5, 2019. 4. Lowery MA, et al. Lancet Gastroenterol Hepatol. 2019;4:711-720.

ClarIDHy: Study design and endpoints



monitored the safety data throughout the study

- Primary endpoint: PFS by blinded independent radiology center (IRC)
- Secondary endpoints included: safety and tolerability; PFS by local review; OS; objective response rate; quality of life (QoL)[†]; pharmacokinetics/pharmacodynamics
- Sample size of ~186 patients based on hazard ratio (HR)=0.5, 96% power, 1-sided alpha=0.025
- 780 patients were screened for IDH1 mutations across 49 sites and 6 countries

*IDH1 mutation status prospectively confirmed by NGS-based Oncomine™ Focus Assay on formalin-fixed, paraffin-embedded tumor tissue in a Clinical Laboratory Improvement Amendments-certified laboratory. †Assessed using EQ-5D-5L, EORTC QLQ-C30, EORTC QLQ-BIL21, and PGI questions.


ECOG PS=Eastern Cooperative Oncology Group Performance Status; EORTC=European Organisation for Research and Treatment of Cancer; EQ-5D-5L=5-level EuroQoL-5 Dimension questionnaire; FU=fluorouracil; NGS=next-generation sequencing; PGI=Patient Global Impression; QD=once daily; QLQ-BIL21=Cholangiocarcinoma and Gallbladder Cancer module; QLQ-C30=Quality of Life Questionnaire Core 30; RECIST=Response Evaluation Criteria in Solid Tumors.

ClarIDHy: Baseline characteristics

Characteristic	lvosidenib (n=124)	Placebo (n=61)
Randomization strata, n (%) 1 prior line of therapy	66 (53.2)	33 (54.1)
2 prior lines of therapy	58 (46.8)	28 (45.9)
IDH1 mutation, n (%) R132C	84 (67.7)	45 (73.8)
R132L/G/S/H	21 (16.9); 17 (13.7); 2 (1.6); 0	7 (11.5); 6 (9.8); 1 (1.6); 2 (3.3)
ECOG PS score at baseline,* n (%) 0	49 (39.5)	19 (31.1)
1	74 (59.7)	41 (67.2)
Cholangiocarcinoma type at diagnosis, n (%) Intrahepatic	111 (89.5)	58 (95.1)
Extrahepatic/Perihilar	5 (4.0)	1 (1.6)
Unknown	8 (6.5)	2 (3.3)
Extent of disease at screening Local/regional	9 (7.3)	5 (8.2)
Metastatic	115 (92.7)	56 (91.8)

*Two (2) patients had an ECOG worsen to 2 (placebo) and 3 (ivosidenib) at baseline assessment upon study start.


ClarIDHy: PFS by IRC



ClarIDHy: Ivosidenib efficacy consistent across subgroups* PFS by IRC

	Events/N	Hazard ratio (HR)	HR	Lower 95% CI	Upper 95% CI
Overall	100/405		0.37	0.252	0.543
anava ana yanetare	126/185		0.57	0.252	0.545
Prior lines of therapy	00/100	_	0.07	0.040	0.010
1	66/106		0.37	0.219	0.612
≥2	60/79	8	0.41	0.234	0.730
Gender					
Female	74/117		0.36	0.220	0.589
Male	52/68		0.45	0.249	0.811
Extent of disease at screening		- 15			
Locally advanced	7/14		0.20	0.035	1.111
Metastatic	119/171		0.41	0.277	0.601
Cancer type at initial diagnosis					
Intrahepatic cholangiocarcinoma	114/169		0.38	0.257	0.567
extrahepatic cholangiocarcinom	a 3/6				
unknown	9/10				
ECOG PS score at baseline					
0	41/68	— — —	0.26	0.124	0.540
≥1	85/117		0.52	0.332	0.803
Regions					
North America	83/124		0.40	0.249	0.631
Europe	34/49	·	0.39	0.188	0.830
Asia	9/12		0.42	0.110	1.597
*Subgroups with events number ≤5 or numl patients ≤10 were not plotted.	ber of	0 Favors ivosidenib 1 Favors placebo	2		8

ClarIDHy: OS by intent-to-treat (ITT)



*Patients without documentation of death at the data cutoff date were censored at the date the patient was last known to be alive or the data cutoff date, whichever was earlier. **1.** Watkins C, et al. *Pharm Stat.* 2013;12:348-357. **2.** Robins JM, Tsiatis AA. *Commun Stat Theory Methods.* 1991;20:2609-2631.

ClarIDHy: Treatment-emergent adverse events (TEAEs)

	Placebo (n=59)	lvosidenib (n=121)	Total ivosidenib (n=156)*
Any TEAE, n (%)	57 (96.6)	115 (95.0)	146 (93.6)
Most common TEAEs	s, <mark>n (%)</mark>		÷
Nausea	15 (25.4)	43 (35.5)	50 (32.1)
Diarrhea	9 (15.3)	37 (30.6)	45 (28.8)
Fatigue	10 (16.9)	32 (26.4)	37 (23.7)
Cough	5 (8.5)	25 (20.7)	30 (19.2)
Abdominal pain	8 (13.6)	26 (21.5)	29 (18.6)
Ascites	9 (15.3)	25 (20.7)	29 (18.6)
Decreased appetite	11 (18.6)	23 (19.0)	27 (17.3)
Anemia	3 (5.1)	18 (14.9)	25 (16.0)
Vomiting	10 (16.9)	23 (19.0)	25 (16.0)

Grade <u>>3</u> TEAE: 35.6% for placebo vs. 46.2% for total ivosidenib. Most common (placebo vs. total ivosidenib): ascites (6.8% vs. 7.7%), bilirubin increase (1.7% vs. 5.8%), anemia (0% vs. 5.1%), AST increase (1.7% vs. 5.1%)

 TEAEs leading to discontinuation were more common for placebo (8.5% vs. 5.8%) than total ivosidenib

 TEAEs leading to dose reductions (2.6% vs. 0%) and interruptions (26.3% vs. 16.9%) were more common for total ivosidenib relative to placebo

*Total ivosidenib includes 35 patients initially assigned to placebo who had crossed over to ivosidenib upon radiographic disease progression and unblinding. >15% TEAEs based on total ivosidenib

ClarIDHy: QoL results

EORTC QLQ-C30 Physical Function Score, change from baseline at C2D1	lvosidenib (n=62)	Placebo* (n=20)
Least square mean (SE) [†]	-3.4 (1.8)	-13.1 (3.0)
Difference (95% CI) vs. placebo	9.8 (2.8, 16.7)	-

- Change from baseline on physical functioning at C2D1[‡] favored ivosidenib where placebo patients had a significantly larger (P=0.006[§]) and clinically meaningful decline in EORTC QLQ-C30 Physical Functioning score compared with ivosidenib patients
- Change from baseline on emotional functioning at C2D1[‡] favored ivosidenib where placebo patients had worsened emotional functioning than ivosidenib patients based on EORTC QLQ-C30 Emotional Functioning and QLQ-BIL21 Anxiety symptom scores
- Data limited by small sample size at post-baseline time points

⁵MMRM analysis of the change from baseline subscale score was applied, with baseline score, treatment, visit, and treatment-by-visit as fixed effects, and patient as random effect. Visit was treated as a categorical variable. Compound symmetry covariance matrix was used. P-value was not adjusted for multiplicity.

^{*}Analyses focused on data from patients randomized to placebo, before crossover.

[†]Higher score is better.

[‡]Analyses focused on C2D1 considering the availability of QoL data.

¹²⁻ to 13-point score decrease estimated from anchor-based analyses represents clinically meaningful worsening.

C2D1=Day 1 of Cycle 2; MMRM=mixed-effect models with repeated measurements; SE=standard error.

Conclusions

- Ivosidenib significantly improved PFS relative to placebo (HR=0.37 [95% CI 0.25, 0.54]; P<0.001) in previously treated patients with mIDH1 advanced cholangiocarcinoma
- Ivosidenib resulted in a numerical improvement in OS compared with placebo based on ITT, and a significant improvement in OS vs. placebo when adjusting for crossover using the RPSFT method (HR=0.46 [95% CI 0.28, 0.75]; P<0.001)
- Ivosidenib 500 mg QD demonstrated a favorable safety profile
- Ivosidenib was associated with better physical and emotional functioning compared with placebo based on EORTC QLQ-C30 and QLQ-BIL21 QoL scores
- These pivotal data demonstrate the clinical relevance and benefit of ivosidenib in mIDH1 cholangiocarcinoma, and establish the role for genomic testing in this rare cancer with a high unmet need